Pcn158 - The Added Value of Personalized Follow-Up for Chronic Lymphocytic Leukemia Patients

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.241
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Precise Determination of Primary Cytogenetic Abnormalities Provides Added Value for Stratification of Chronic Lymphocytic Leukemia Patients

Neoplasma
Cancer Research
2019English

A Personalized Framework for Dynamic Modeling of Disease Trajectories in Chronic Lymphocytic Leukemia

IEEE Transactions on Biomedical Engineering
Biomedical Engineering
2016English

Chronic Lymphocytic Leukemia

Current Opinion in Hematology
Hematology
1998English

Chronic Lymphocytic Leukemia

Orvosi Hetilap
Medicine
2008English

Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3-Year Follow-Up

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Chronic Lymphocytic Leukemia

ASH Image Bank
2003English

Chronic Lymphocytic Leukemia

Molecular and Translational Medicine
2018English

Chronic Lymphocytic Leukemia

Hematology/Oncology Clinics of North America
OncologyHematology
2004English

Novel Agents for Chronic Lymphocytic Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy